Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 8/20 | 0.61 |
| ▸ | UBE2M | P61081 | 12/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 12/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12907878 | 0.87 | CASR (0.81) | CASR | |
| SCHEMBL926221 | 0.81 | CASR (0.86) | CASR | |
| SCHEMBL927091 | 0.76 | CASR (1.00) | CASR | |
| SCHEMBL18657896 | 0.69 | UBE2M (1.00) | UBE2MDCUN1D1 | |
| SCHEMBL18657880 | 0.69 | UBE2M (1.00) | UBE2MDCUN1D1 | |
| SCHEMBL926633 | 0.69 | CASR (0.74) | CASR | |
| SCHEMBL926103 | 0.68 | CASR (0.74) | CASR | |
| Hydrochloric Acid SCHEMBL925831 | 0.68 | CASR (0.73) | CASR | |
| SCHEMBL926455 | 0.67 | CASR (0.69) | CASR | |
| SCHEMBL4676983 | 0.67 | CASR (0.63) | CASRUBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1965805-B1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2009-12-02 | — | — | EP | claimed |
| EP-1965805-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | Proskelia SAS (FR) | 2008-09-10 | — | — | EP | claimed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | claimed |
| WO-2007060026-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2007-05-31 | — | — | WO | claimed |
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1965805-B1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2009-12-02 | — | — | EP | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | UTS2R, CACNA1A, CACNA1E | CASR 606/4885UBE2M 598/4885DCUN1D1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.